NINLARO® (ixazomib) is available in the following capsule strengths:

- 4 mg: Light orange gelatin capsule imprinted with the logo on the cap and 4 mg on the body in black ink
- 3 mg: Light gray gelatin capsule imprinted with the logo on the cap and 3 mg on the body in black ink
- 2.3 mg: Light pink gelatin capsule imprinted with the logo on the cap and 2.3 mg on the body in black ink

**WARNINGS AND PRECAUTIONS (cont’d)**

**Hepatotoxicity:** has been reported with NINLARO. Drug-induced liver injury has been reported with NINLARO. Clinically significant liver injury has been reported with NINLARO. Deaths have been reported with NINLARO.

**Embryo-Fetal Toxicity:** NINLARO is a category D pregnancy exposure risk. Advise pregnant women of the risk to a fetus.

**NINLARO® (ixazomib): What you need to know**

**Dosage and administration:**

The recommended starting dose of NINLARO is 4 mg (one capsule) in combination with lenalidomide and dexamethasone.

**Schedule:**

NINLARO® is taken once a week for the first 3 weeks of a 4-week cycle.

**Maximum recommended dose:** should be continued until disease progression or unacceptable toxicity.

**INDICATION AND USAGE:**

NINLARO is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.

**Limitations of Use:**

NINLARO is not recommended for use in the maintenance setting or in newly diagnosed multiple myeloma in combination with lenalidomide and dexamethasone outside of controlled clinical trials.

**ADVERSE REACTIONS:**

The most common adverse reactions (≥20%) in the NINLARO regimen compared to placebo in combination with lenalidomide plus dexamethasone, respectively were thrombocytopenia (59%, 4%), total bilirubin (46%, 1%), anemia (35%, 13%), and creatinine (29%, 6%). Serious adverse reactions reported in ≥5% of patients in the NINLARO regimen included neutropenia (9%), thrombocytopenia (9%), anemia (9%), constipation (6%), and diarrhea (6%).

**DRUG INTERACTIONS:** Avoid concomitant administration of NINLARO with strong CYP3A inhibitors.

**USE IN SPECIFIC POPULATIONS:**

**Lactation:** NINLARO is not recommended for breastfeeding during treatment with NINLARO and for 90 days after the last dose.

**Hepatic Impairment:** NINLARO starting dose should be reduced to 3 mg for patients with mild to moderate or severe hepatic impairment.

**Renal Impairment:** Reduce the NINLARO starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease requiring dialysis. NINLARO is not dialyzable.

**DOSING GUIDE**

- 4 mg: Light orange gelatin capsule imprinted with the logo on the cap and 4 mg on the body in black ink
- 3 mg: Light gray gelatin capsule imprinted with the logo on the cap and 3 mg on the body in black ink
- 2.3 mg: Light pink gelatin capsule imprinted with the logo on the cap and 2.3 mg on the body in black ink

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
The NINLARO® (ixazomib) regimen offers the convenience of oral administration¹⁻³

**Dosing**

- The recommended starting dose of NINLARO is 4 mg (one capsule) in combination with lenalidomide and dexamethasone²

**Communicating with your patients**

Tips and reminders have been included in this brochure to facilitate communication with patients. You can recognize them by their orange callout box.

Share the following information at the start of treatment to ensure patients and caregivers are well informed:

- Drug and indication
- Dose and dosing schedule
- Start date
- Handling instructions
- Administration and what to do if a dose is missed or too much NINLARO is taken
- Food and drug interactions
- Side effects and management

*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone. A 3-mg starting dose is recommended for patients with moderate or severe hepatic impairment and patients with severe renal impairment or end-stage renal disease requiring dialysis. A 2.3-mg dose is also available for subsequent dose reductions due to adverse reactions (ARs).*

---

**CONTENTS:**

**DOsing**

Pages 3-5

**DOsing Considerations**

Pages 6-9

**Adverse reactions**

Pages 10-14

**DoSe Modifications**

Pages 15-19

**Safety**

Pages 20-21

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
Dosing schedule

• The recommended dosing schedule for each 28-day treatment cycle of:

  — NINLARO is 4 mg (one capsule) administered orally once a week on days 1, 8, and 15
  — Lenalidomide is 25 mg administered orally daily on days 1 through 21
  — Dexamethasone is 40 mg administered orally on days 1, 8, 15, and 22

• Advise patients to take NINLARO once a week on the same day and at approximately the same time for the first 3 weeks of a 4-week cycle. The importance of carefully following all dosage instructions should be discussed with patients starting treatment. Advise patients to take the recommended dosage as directed because overdosage has led to deaths.

For more information on dosing administration requirements, see the next page.
NINLARO® (ixazomib) dosing considerations

NINLARO should not be taken with food. Food may interfere with the absorption of NINLARO, which may lower levels of the medication in the blood and possibly reduce effectiveness.

- NINLARO should be taken on an empty stomach or at least 1 hour before or at least 2 hours after food
- NINLARO should not be taken at the same time as dexamethasone because dexamethasone should be taken with food
- No body surface area dosing is required
- NINLARO should be swallowed whole with water and should not be crushed, chewed, or opened
- If a NINLARO dose is delayed or missed, the dose should be taken only if the next scheduled dose is at least 72 hours away
  — A double dose should not be taken to make up for the missed dose
  — If vomiting occurs after taking a dose, the patient should not repeat the dose. The patient should resume dosing at the time of the next scheduled dose
- Antiviral prophylaxis should be considered in patients being treated with NINLARO to decrease the risk of herpes zoster reactivation

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
Considerations prior to initiating a new cycle of therapy¹

- Absolute neutrophil count should be at least 1000/mm³
- Platelet count should be at least 75,000/mm³. Monitor platelet counts at least monthly during treatment with NINLARO
- Nonhematologic toxicities should, at the healthcare provider’s discretion, generally be recovered to patient’s baseline condition or grade 1 or lower

Communication is key

- There’s no such thing as overcommunicating
- To verify comprehension, have patients repeat information in their own words
Storage

- NINLARO® (ixazomib) may be stored at room temperature. Do not store above 30°C (86°F). Do not freeze
- Store capsules in original packaging until immediately prior to use

Handling and disposal

- NINLARO is cytotoxic. Capsules should not be opened, crushed, or chewed. Direct contact with the capsule contents should be avoided
- NINLARO is available in single dose packs (1 pill) and complete monthly dose packs (3 pills)
- Any unused medicinal product or waste material should be disposed of in accordance with local requirements

Capsule breakage

- In case of capsule breakage, avoid direct contact of capsule contents with the skin or eyes. If skin contact occurs, wash thoroughly with soap and water. If contact occurs with the eyes, flush thoroughly with water

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
Capsule warnings

Capsule should not be crushed

Capsule should not be chewed

Capsule should not be opened

Capsule should not be removed from original packaging until time of consumption
Nonhematologic ARs occurring in ≥5% of patients between the NINLARO® (ixazomib) regimen* and the Rd regimen (n=359) Difference

<table>
<thead>
<tr>
<th>AR</th>
<th>NINLARO regimen (n=361)</th>
<th>All grades</th>
<th>Grade 3</th>
<th>Grade 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>52%</td>
<td>10%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>35%</td>
<td>&lt;1%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Peripheral neuropathies†</td>
<td>32%</td>
<td>2%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>32%</td>
<td>2%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Peripheral edema‡</td>
<td>27%</td>
<td>2%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Back pain†</td>
<td>27%</td>
<td>&lt;1%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Rash†</td>
<td>27%</td>
<td>3%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Upper respiratory‡ tract infection</td>
<td>27%</td>
<td>1%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>26%</td>
<td>1%</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td>Bronchitis</td>
<td>22%</td>
<td>2%</td>
<td>0</td>
<td></td>
</tr>
</tbody>
</table>

*The NINLARO regimen included NINLARO+lenalidomide+dexamethasone. The Rd regimen included placebo+lenalidomide+dexamethasone.
†Represents a pooling of preferred terms.
‡At the time of the final analysis, these adverse reactions no longer met the criterion for a ≥ 5% difference between the NINLARO regimen and the placebo regimen.

Additional safety information†

- Serious ARs reported in ≥2% of patients included diarrhea (3%), thrombocytopenia (2%) and bronchitis (2%)

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
with a ≥5% difference
the Rd regimen

<table>
<thead>
<tr>
<th></th>
<th>Rd regimen (n=359)</th>
<th>Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All grades</td>
<td>All grades</td>
</tr>
<tr>
<td></td>
<td>Grade 3</td>
<td>Grade 4</td>
</tr>
<tr>
<td>43%</td>
<td>3%</td>
<td>0</td>
</tr>
<tr>
<td>28%</td>
<td>&lt;1%</td>
<td>0</td>
</tr>
<tr>
<td>24%</td>
<td>2%</td>
<td>0</td>
</tr>
<tr>
<td>23%</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>21%</td>
<td>1%</td>
<td>0</td>
</tr>
<tr>
<td>24%</td>
<td>3%</td>
<td>0</td>
</tr>
<tr>
<td>16%</td>
<td>2%</td>
<td>0</td>
</tr>
<tr>
<td>23%</td>
<td>1%</td>
<td>0</td>
</tr>
<tr>
<td>13%</td>
<td>&lt;1%</td>
<td>0</td>
</tr>
<tr>
<td>17%</td>
<td>2%</td>
<td>&lt;1%</td>
</tr>
</tbody>
</table>

ADVERSE REACTIONS

NINLARO
(ixazomib) capsules
4 mg | 3 mg | 2.3 mg
Hematologic adverse events

<table>
<thead>
<tr>
<th></th>
<th>NINLARO® (ixazomib) regimen* (n=361)</th>
<th>Rd regimen* (n=359)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Any grade</td>
<td>Grades 3-4</td>
</tr>
<tr>
<td><strong>Thrombocytopenia</strong></td>
<td>85%</td>
<td>30%</td>
</tr>
<tr>
<td><strong>Neutropenia</strong></td>
<td>74%</td>
<td>34%</td>
</tr>
</tbody>
</table>

Represents pooled information from adverse event and laboratory data.

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
Dose tolerability

The NINLARO® (ixazomib) triplet regimen* demonstrated a safety profile appropriate for long-term† treatment§

- The median dose intensity for NINLARO and placebo was high and similar in the NINLARO and Rd regimens: 97.8% and 100%, respectively.
- Relative dose intensity was calculated as $100 \times \left( \frac{\text{total amount of dose taken}}{\text{total planned dose over treatment cycles}} \right)^5$
- The most common adverse reactions (≥ 20%) in the NINLARO regimen compared to placebo in combination with lenalidomide plus dexamethasone, respectively were thrombocytopenia (85%, 67%; pooled from adverse event and laboratory data), neutropenia (74%, 70%; pooled from adverse event and laboratory data), diarrhea (52%, 43%), constipation (35%, 28%), peripheral neuropathy (32%, 24%), nausea (32%, 23%), edema peripheral (27%, 21%), rash (27%, 16%), vomiting (26%, 13%), and bronchitis (22%, 17%). Serious adverse reactions reported in ≥ 2% of patients in the NINLARO regimen included diarrhea (3%), thrombocytopenia (2%), and bronchitis (2%)¹

---

*The NINLARO regimen included NINLARO+lenalidomide+dexamethasone. The Rd regimen included placebo+lenalidomide+dexamethasone.¹
†Used herein to refer to treatment to disease progression or unacceptable toxicity.¹
**Prepare patients for side effects and dosing concerns**

**Concomitant medications may be given for prophylaxis and/or management of symptoms**\(^7,^8\)

<table>
<thead>
<tr>
<th>Condition</th>
<th>Prophylaxis/symptomatic</th>
<th>Consider*</th>
</tr>
</thead>
<tbody>
<tr>
<td>GI toxicity: diarrhea</td>
<td>Symptomatic</td>
<td>Antidiarrheal (eg, loperamide)</td>
</tr>
<tr>
<td>GI toxicity: nausea/vomiting</td>
<td>Prophylaxis or symptomatic</td>
<td>Antiemetics, antinauseants (eg, ondansetron, metoclopramide)</td>
</tr>
<tr>
<td>Viral infection: herpes zoster (reactivation)</td>
<td>Prophylaxis† or symptomatic</td>
<td>Antivirals†</td>
</tr>
<tr>
<td>Rash</td>
<td>Prophylaxis or symptomatic</td>
<td>Antihistamines (eg, cetirizine) or corticosteroids (oral or topical; eg, prednisone)</td>
</tr>
</tbody>
</table>

*These medications and supportive therapies are examples of appropriate supportive care that were permitted in the phase 3 clinical trial.\(^6\)
†Patients treated in the NINLARO regimen who received antiviral prophylaxis had a lower incidence (1%) of herpes zoster infection compared with patients who did not receive prophylaxis (10%).\(^1\)

Encourage patients and caregivers to report any side effects early so appropriate management measures can be taken.

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.
Management of some ARs may require modification of the NINLARO dose

**NINLARO dose modification schedule**

<table>
<thead>
<tr>
<th>Dose</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>4 mg</td>
<td>Recommended starting dose</td>
</tr>
<tr>
<td>3 mg</td>
<td>First dose reduction&lt;br&gt;Recommended starting dose for patients with:&lt;br&gt;</td>
</tr>
<tr>
<td></td>
<td>• Moderate or severe hepatic impairment(^\d)&lt;br&gt;</td>
</tr>
<tr>
<td></td>
<td>• Severe renal impairment(^\S)&lt;br&gt;</td>
</tr>
<tr>
<td></td>
<td>• End-stage renal disease requiring dialysis</td>
</tr>
<tr>
<td>2.3 mg</td>
<td>Second dose reduction</td>
</tr>
<tr>
<td>If toxicities continue</td>
<td>Discontinuation</td>
</tr>
</tbody>
</table>

Not actual capsule size.

- No dose adjustment is required for:
  - Elderly patients
  - Patients with mild to moderate renal impairment\(^\S\)
  - Patients with mild hepatic impairment\(^\d\)
- NINLARO can be taken if patient is on dialysis

\(^\d\)Hepatic impairment: mild, total bilirubin ≤1.5 × ULN; moderate, total bilirubin >1.5-3 × ULN; severe, total bilirubin >3 × ULN.

\(^\S\)Renal impairment: mild to moderate, creatinine clearance ≥30 mL/min; severe, creatinine clearance <30 mL/min.

ULN=upper limit of normal.
The first dose modification step for overlapping hematologic toxicities is to reduce the lenalidomide dose after withholding NINLARO and lenalidomide¹

- Refer to the lenalidomide Prescribing Information for the dose reduction steps for these toxicities

---

Dose modification guidelines for the NINLARO® (ixazomib) regimen¹*

<table>
<thead>
<tr>
<th>Hematological toxicities</th>
<th>Recommended actions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thrombocytopenia (platelet count)</td>
<td>• Withhold NINLARO and lenalidomide until platelet count is at least 30,000/mm³&lt;br&gt;• Following recovery, resume lenalidomide at the next lower dose according to its Prescribing Information and resume NINLARO at its most recent dose&lt;br&gt;• If platelet count falls to &lt;30,000/mm³ again, withhold NINLARO and lenalidomide until platelet count is at least 30,000/mm³&lt;br&gt;• Following recovery, resume NINLARO at the next lower dose and resume lenalidomide at its most recent dose†</td>
</tr>
</tbody>
</table>
**Hematological toxicities**

**Neutropenia (absolute neutrophil count)**

<table>
<thead>
<tr>
<th>Absolute neutrophil count &lt;500/mm³</th>
<th><strong>Recommended actions</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>· Withhold NINLARO and lenalidomide until absolute neutrophil count is at least 500/mm³. Consider adding G-CSF as per clinical guidelines</td>
</tr>
<tr>
<td></td>
<td>· Following recovery, resume lenalidomide at the next lower dose according to its Prescribing Information and resume NINLARO at its most recent dose</td>
</tr>
<tr>
<td></td>
<td>· If absolute neutrophil count falls to &lt;500/mm³ again, withhold NINLARO and lenalidomide until absolute neutrophil count is at least 500/mm³</td>
</tr>
<tr>
<td></td>
<td>· Following recovery, resume NINLARO at the next lower dose and resume lenalidomide at its most recent dose†</td>
</tr>
</tbody>
</table>

*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone.
†For additional occurrences, alternate dose modification of lenalidomide and NINLARO. G-CSF=granulocyte-colony stimulating factor.
## Dose modification guidelines for the NINLARO<sup>®</sup> (ixazomib) regimen<sup>1*</sup> (cont’d)

### Nonhematological toxicities

<table>
<thead>
<tr>
<th>Rash</th>
<th>Recommended actions</th>
</tr>
</thead>
</table>
| Grade<sup>†</sup> 2 or 3 | · Withhold lenalidomide until rash recovers to grade 1 or lower  
                           · Following recovery, resume lenalidomide at the next lower dose according to its Prescribing Information  
                           · If grade 2 or 3 rash occurs again, withhold NINLARO and lenalidomide until rash recovers to grade 1 or lower  
                           · Following recovery, resume NINLARO at the next lower dose and resume lenalidomide at its most recent dose<sup‡</sup> |
| Grade 4               | · Discontinue treatment regimen                                                                                                                                 |

### Peripheral neuropathy

| Grade 1 peripheral neuropathy with pain or grade 2 peripheral neuropathy | Withhold NINLARO until peripheral neuropathy recovers to grade 1 or lower without pain or patient’s baseline  
                                                                                  Following recovery, resume NINLARO at its most recent dose |
| Grade 2 peripheral neuropathy with pain or grade 3 peripheral neuropathy | Withhold NINLARO. Toxicities should, at the healthcare provider’s discretion, generally recover to patient’s baseline condition or grade 1 or lower prior to resuming NINLARO  
                                                                                  Following recovery, resume NINLARO at the next lower dose |
| Grade 4 peripheral neuropathy | Discontinue treatment regimen                                                                                                                                 |
Other nonhematological toxicities

<table>
<thead>
<tr>
<th>Other grade 3 or 4 nonhematological toxicities</th>
</tr>
</thead>
</table>

**Recommended actions**

• Withhold NINLARO. Toxicities should, at the healthcare provider’s discretion, generally recover to patient’s baseline condition or grade 1 or lower prior to resuming NINLARO.

• If attributable to NINLARO, resume NINLARO at the next lower dose following recovery.

---

**Rash maculo-papular**
Grade 2: macules/papules covering 10%–30% body surface area (BSA) with or without symptoms (e.g., pruritus, burning, tightness); limiting instrumental activities of daily living (ADL); rash covering >30% BSA with or without mild symptoms.
Grade 3: macules/papules covering >30% BSA with moderate or severe symptoms; limiting self-care ADL.

**Peripheral sensory neuropathy**
Grade 1: asymptomatic.
Grade 2: moderate symptoms; limiting instrumental ADL.
Grade 3: severe symptoms; limiting self-care ADL.
Grade 4: life-threatening consequences; urgent intervention indicated.

---

**The first dose modification step for overlapping toxicities of rash is to withhold/reduce lenalidomide**

*The NINLARO regimen includes NINLARO+lenalidomide+dexamethasone.
†Grading based on National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03.
‡For additional occurrences, alternate dose modification of lenalidomide and NINLARO.

---

**Provide patients with close follow-up support**

• Encourage patients to report any side effects as they occur so the appropriate management measures can be taken.

---

For additional information regarding lenalidomide and dexamethasone, please see their Prescribing Information.
IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

• **Thrombocytopenia** has been reported with NINLARO. Platelet nadirs typically occurred between Days 14-21 of each 28-day cycle and recovered to baseline by the start of the next cycle. Grade 3 thrombocytopenia was reported in 17% of patients in the NINLARO regimen and Grade 4 thrombocytopenia was reported in 13% in the NINLARO regimen. During treatment, monitor platelet counts at least monthly, and consider more frequent monitoring during the first three cycles. Manage thrombocytopenia with dose modifications and platelet transfusions as per standard medical guidelines.

• **Gastrointestinal Toxicities**, including diarrhea, constipation, nausea and vomiting were reported with NINLARO and may occasionally require the use of antidiarrheal and antiemetic medications, and supportive care. Diarrhea resulted in the discontinuation of one or more of the three drugs in 3% of patients in the NINLARO regimen and 2% of patients in the placebo regimen. Adjust dosing for Grade 3 or 4 symptoms.

• **Peripheral Neuropathy** was reported with NINLARO. The most commonly reported reaction was peripheral sensory neuropathy (24% and 17% in the NINLARO and placebo regimens, respectively). Peripheral motor neuropathy was not commonly reported in either regimen (<1%). Peripheral neuropathy resulted in discontinuation of one or more of the three drugs in 4% of patients in the NINLARO regimen and <1% of patients in the placebo regimen. During treatment, monitor patients for symptoms of neuropathy and consider adjusting dosing for new or worsening peripheral neuropathy.

• **Peripheral Edema** was reported with NINLARO. Evaluate for underlying causes and provide supportive care, as necessary. Adjust dosing of NINLARO for Grade 3 or 4 symptoms or dexamethasone per its prescribing information.

• **Cutaneous Reactions**, including a fatal case of Stevens-Johnson syndrome, were reported with NINLARO. If Stevens-Johnson syndrome occurs, discontinue NINLARO and manage as clinically indicated. Rash, most commonly maculo-papular and macular rash, was reported with NINLARO. Rash resulted in discontinuation of one or more of the three drugs in <1% of patients in both regimens. Manage rash with supportive care or with dose modification if Grade 2 or higher.

• **Thrombotic Microangiopathy** has been reported with NINLARO. Fatal cases of thrombotic microangiopathy, including thrombotic thrombocytopenic purpura/hemolytic uremic syndrome (TTP/HUS), have been reported in patients who received NINLARO. Monitor for signs and symptoms of TTP/HUS. If the diagnosis is suspected, stop NINLARO and evaluate. If the diagnosis of TTP/HUS is excluded, consider restarting NINLARO. The safety of reinitiating NINLARO therapy in patients previously experiencing TTP/HUS is not known.

Please see Important Safety Information within the Safety tab and accompanying NINLARO (ixazomib) full Prescribing Information.